Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Takaoka, Yuri; Miura, Kouichi; Morimoto, Naoki; Kakizaki, Satoru; Ikegami, Tadashi; Ueno, Takashi; Arai, Hajime; Hatanaka, Takeshi; Tahara, Toshiyuki; Murohisa, Toshimitsu; Namikawa, Masashi; Naganuma, Akira; Ohtake, Takaaki; Horiuchi, Katsuhiko; Asano, Takeharu; Kamoshida, Toshiro; Tano, Shigeo; Fukaya, Yukimura; Kosone, Takashi; Watanabe, Shunji; Tsukui, Mamiko; Hirosawa, Takuya; Nomoto, Hiroaki; Goka, Rie; Maeda, Hiroshi; Sato, Naoto; Isoda, Norio; Yamamoto, Hironori

doi:10.2957/kanzo.61.276

Cited by 2 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports revealed that 50-53% of patients showed an unchanged or worsened hepatic function, as determined by the CP score and/or the Model for End-stage Liver Disease (MELD) score, despite obtaining an SVR. 5,6,11 We expanded our multicenter study in the northern Kanto area of Japan 12 and evaluated the real-world efficacy and safety of 12-week SOF/VEL treatment for patients with decompensated liver cirrhosis. In addition, we identified factors that interfered with the improvement of liver function despite the achievement of SVR.…”

Section: Introductionmentioning

confidence: 99%

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Takaoka

Miura

Morimoto

et al. 2020

Hepatology Research

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate the real world efficacy and safety of 12 week sofosbuvir/velpatasvir (SOF/VEL) treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus (HCV) infection. Methods: A total 72 of patients with Child-Pugh (CP) class B or C were enrolled. We evaluated the sustained virologic response at 12 weeks after the end of treatment (SVR12), adverse events (AEs), and changes in the liver function. Results: All participants had genotype 1 or 2 HCV infection. At baseline, the numbers of patients with CP class B and C were 59 and 13, respectively. The overall SVR12 rate was 95.8% (69/72); 94.9% (56/59) in CP class B and 100% (13/13) in CP class C. The serum albumin level, prothrombin time and ascites were significantly improved (P<0.01); however, the serum bilirubin level and encephalopathy did not improve. Among patients who achieved SVR12, 75.0% showed an improvement in their CP score, while 5.9% showed a worsening. The presence of large portosystemic shunt (diameter ≥6 mm) and hyperbilirubinemia (≥2.0 mg/dL) were independent factors that interfered with the improvement in the CP score (P<0.

show abstract

Section: Introductionmentioning

confidence: 99%

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Takaoka

Miura

Morimoto

et al. 2020

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, SOF/VEL was firstly indicated for decompensated liver cirrhosis. It was confirmed that this agent improves the serum albumin level, prothrombin time, and sometimes the serum ammonia level [ 12 ] after eradication of HCV. However, it has not been confirmed whether hepatic encephalopathy, ascites, and pleural effusion disappear clinically after the eradication of HCV by SOF/VEL administration.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, our case showed marked improvements in the serum ammonia level (112→75 μg/dL), albumin level (3.3→4.1 g/dL), and prothrombin time (70.9→85.8%), respectively. With regard to these findings, Takaoka et al [ 12 ] administered SOF/VEL for 12 weeks to 43 patients with decompensated cirrhosis, and they reported that the serum albumin level improved to 3.2 g/dL on average, and prothrombin time improved to 70% on average. Considering their results, our case demonstrated marked improvements in the serum albumin level and prothrombin time.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, they were in a lifethreatening state and eradication of HCV was not possible. Now, a new DAA, sofosbuvir/velpatasvir (SOF/VEL), is indicated for eradicating HCV in patients with decompensated HCV-associated liver cirrhosis [11,12]. We recently encountered an HCV-associated decompensated cirrhotic patient whose hepatic encephalopathy, ascites, and pleural effusion disappeared after HCV-RNA became negative due to the administration of SOF/VEL with marked improvement of the serum ammonia level, serum albumin level, prothrombin time, and platelet count.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir

Tarao¹,

Nozaki

Komatsu

2021

Case Rep Gastroenterol

View full text Add to dashboard Cite

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Moreover, many DAAs include an indication for compensated liver cirrhosis. However, patients with decompensated HCV-associated cirrhosis have hitherto not been indicated for therapy with DAAs. Recently, a new DAA, sofosbuvir/velpatasvir (SOF/VEL), was indicated for decompensated HCV-associated cirrhotic patients. Actually, it has been shown to eradicate HCV in many cases. However, it is not clear whether hepatic encephalopathy, ascites, and pleural effusion in patients with decompensated HCV-associated cirrhosis disappear by SOF/VEL treatment. Recently, we encountered a decompensated HCV-associated cirrhosis patient who showed the disappearance of hepatic encephalopathy, ascites, and pleural effusion with marked improvement of serum ammonia level, albumin level, prothrombin time, and platelet count after the eradication of HCV by the administration of SOF/VEL. Her consciousness was cloudy and it took many hours for the preparation of each meal just before SOF/VEL treatment, but after the disappearance of HCV-RNA by the therapy, her consciousness became clear and she could prepare meals in a short time. This case suggests the possibility of improvement from decompensated HCV-associated liver cirrhosis to compensated liver cirrhosis with disappearance of hepatic encephalopathy, ascites, and pleural effusion by SOF/VEL therapy.

show abstract

Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Cited by 2 publications

References 3 publications

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir

Contact Info

Product

Resources

About